Rankings
▼
Calendar
TELO Q4 2022 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$46M
Q4 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$487,096
Net Income
-$487,096
EPS (Diluted)
$-0.02
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$255,791
Free Cash Flow
-$255,791
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$48,730
Total Liabilities
$986,008
Stockholders' Equity
-$937,278
Cash & Equivalents
$1,419
← FY 2022
All Quarters
Q1 2023 →
